390sek
0,1 %
Date:2024-04-26Time:17:29:35Latest report:Q4-2023List:First NorthTicker:ONCOZ
Market Cap:46 msekEnterprise Value:33 msekNet Sales:- msekEarnings:-15,9 msekEmployees:0ISIN:SE0015504097

Ratios

10-year key figure history for OncoZenge turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for OncoZenge with index and moving average MA50 and MA200.

Stockprice:3,90
MA50:3,89
MA200:3,33
Price/MA200:16,8 %
RSI (14):49,5
Price/MA50:0,1 %

Description

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

Pharmaceuticals